Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Haller, Hermann; Ito, Sadayoshi; Izzo, Joseph L.; Januszewicz, Andrzej; Katayama, Shigehiro; Menne, Jan; Mimran, A; Rabelink, Ton J.; Ritz, Eberhard; Ruilope, Luís M.; Rump, Lars Christian; Viberti, Giancarlo

doi:10.1056/nejmoa1007994

Cited by 761 publications

(553 citation statements)

References 26 publications

Supporting

Mentioning

493

Contrasting

Unclassified

Order By: Relevance

“…In the ROADMAP trial, a phase 3 trial performed in 4447 patients with diabetes mellitus, the rates of diarrhoea and abdominal discomfort were similar in the olmesartan and the placebo arm. 18,19 More recently, a retrospective cohort analysis performed in 45 185 (116 721 patient-years) diabetic patients, compared olmesartan with other sartans and found no significant association between olmesartan and gastrointestinal disease-related hospitalisation. 20 Therefore, the association between enteropathy and olmesartan has been called into question.…”

Section: Resultsmentioning

confidence: 99%

“…Clinical, biological and histological manifestations All 32 patients (100%) had diarrhoea, with a median number of 8 liquid stools per day [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Twenty-four patients (75%) had abdominal pain, which was rarely severe (n = 3).…”

Section: Resultsmentioning

confidence: 99%

“…The median cumulative hospital stay was 29 days . Four patients required intensive care (12 days [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]). Seven patients required enteral nutrition (30 days ) and 10 required parenteral nutrition (29 days ).…”

Section: Outcomementioning

confidence: 99%

See 2 more Smart Citations

Olmesartan-associated enteropathy: results of a national survey

Marthey

Cadiot

Seksik

et al. 2014

Aliment Pharmacol Ther

175

171

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Olmesartan-associated enteropathy: results of a national survey

Marthey

Cadiot

Seksik

et al. 2014

Aliment Pharmacol Ther

175

171

View full text Add to dashboard Cite

show abstract

“…The American Diabetes Association, the European Society of Hypertension and the Japanese Society of Hypertension recommend the use of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ARBs) as a first choice for type 2 diabetes patients with hypertension3, 4, 5. These drugs decrease not only the risk of macroangiopathy6, 7, 8, but also other diabetic complications9, 10, 11, 12, 13. Furthermore, these drugs also delay the onset of diabetes14, 15, 16.…”

Section: Introductionmentioning

confidence: 99%

Switching from low‐dose thiazide diuretics to sodium–glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension

Kimura

Sanada

Shimoda

et al. 2017

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionSodium–glucose cotransporter 2 (SGLT2) inhibitors function to increase urinary glucose excretion and improve glycemic control in individuals with type 2 diabetes mellitus. SGLT2 inhibitors, as well as diuretics, increase urinary volume, which leads to the reduction of blood pressure. The aim of the present study was to compare the effects of SGLT2 inhibitor and thiazide diuretic on blood pressure, metabolic parameters and body mass composition.Materials and MethodsA total of 31 participants were enrolled in the present study. We switched from thiazide diuretics to an SGLT2 inhibitor, ipragliflozin, in participants with type 2 diabetes and hypertension whose blood pressure was controlled with thiazide diuretics. Three months after the switch, we evaluated the effects of such switching on blood pressure, various metabolic parameters and body mass composition.ResultsThere was no significant difference in blood pressure from baseline to 3 months later. However, glycated hemoglobin, fasting plasma glucose and uric acid were significantly decreased after the switch. Body mass index and visceral fat area were also significantly reduced after the switch. Furthermore, urinary albumin excretion was also significantly decreased after the switch.ConclusionsSwitching from thiazide diuretic to an SGLT2 inhibitor, ipragliflozin, markedly improved various metabolic parameters and body mass composition without affecting blood pressure in participants with type 2 diabetes and hypertension.

show abstract

“…4,5 Recent studies have suggested that the use of RAS inhibitors may also be effective in preventing new-onset of chronic kidney disease, particularly in patients with diabetes. 6,7 These results suggest the possibility that early inhibition of the RAS may be an effective strategy for prevention of chronic kidney disease. However, despite the increasing availability of different types of RAS inhibitors for over 20 years, the number of patients with chronic kidney disease is still increasing throughout the world, which suggests that other, non-pharmacological approaches may be required.…”

Section: Introductionmentioning

confidence: 88%

Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy

et al. 2011

View full text Add to dashboard Cite

Previous studies have shown that renin-angiotensin (Ang) system vaccines may be effective for the treatment of hypertension, but their efficacy for the prevention of renal disease is unclear. The aim of this study was to compare the effects of an Ang II type 1 (AT1) receptor vaccine with an Ang II receptor blocker (ARB) and a vasodilator on blood pressure (BP) and renal injury in the L-NAME nephropathy model. Male spontaneously hypertensive rats (SHRs) were divided into six groups and treated transiently with three injections of vehicle or AT1 receptor vaccine (0.1 mg) at age 4, 6 and 8 weeks, or continuously with candesartan cilexetil (0.1 mg kg À1 per day) or hydralazine hydrochloride (5 mg kg À1 per day), then administered NG-nitro-Larginine methyl ester (L-NAME) from age 18 to 21 weeks to induce renal injury. Vaccination against the AT1 receptor caused a significant increase in AT1 receptor titers, and a sustained decrease in BP. L-NAME treatment resulted in a marked increase in proteinuria in the control groups, which was completely suppressed in the AT1 vaccine-treated group, and glomerular injury scores were also significantly decreased. Real-time RT-PCR and immunofluorescence studies revealed increased renin mRNA, and increased glomerular expression of nephrin. Comparable results were seen in rats treated continuously with the ARB candesartan, but not with hydralazine. These results suggest that transient AT1 vaccination is as effective as continuous treatment with ARB, not only for the attenuation of hypertension, but also for the prevention of L-NAME-induced nephropathy in SHR.

show abstract

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Cited by 761 publications

References 26 publications

Olmesartan-associated enteropathy: results of a national survey

Olmesartan-associated enteropathy: results of a national survey

Switching from low‐dose thiazide diuretics to sodium–glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension

Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy

Contact Info

Product

Resources

About